These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21359173)

  • 1. Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
    Pflugfelder A; Eigentler TK; Keim U; Weide B; Leiter U; Ikenberg K; Berneburg M; Garbe C
    PLoS One; 2011 Feb; 6(2):e16882. PubMed ID: 21359173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
    Chang W; Lee SJ; Park S; Choi MK; Hong JY; Kim YS; Maeng CH; Jung HA; Kim S; Lee J
    Melanoma Res; 2013 Apr; 23(2):147-51. PubMed ID: 23411477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
    Croghan GA; Suman VJ; Maples WJ; Albertini M; Linette G; Flaherty L; Eckardt J; Ma C; Markovic SN; Erlichman C
    Cancer; 2010 Jul; 116(14):3463-8. PubMed ID: 20564112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
    Kim KB; Sosman JA; Fruehauf JP; Linette GP; Markovic SN; McDermott DF; Weber JS; Nguyen H; Cheverton P; Chen D; Peterson AC; Carson WE; O'Day SJ
    J Clin Oncol; 2012 Jan; 30(1):34-41. PubMed ID: 22124101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
    Kottschade LA; Suman VJ; Amatruda T; McWilliams RR; Mattar BI; Nikcevich DA; Behrens R; Fitch TR; Jaslowski AJ; Markovic SN
    Cancer; 2011 Apr; 117(8):1704-10. PubMed ID: 21472717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
    Kottschade LA; Suman VJ; Perez DG; McWilliams RR; Kaur JS; Amatruda TT; Geoffroy FJ; Gross HM; Cohen PA; Jaslowski AJ; Kosel ML; Markovic SN
    Cancer; 2013 Feb; 119(3):586-92. PubMed ID: 22915053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
    Hauke RJ; Infante JR; Rubin MS; Shih KC; Arrowsmith ER; Hainsworth JD
    Melanoma Res; 2013 Dec; 23(6):468-73. PubMed ID: 23969699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
    Perez DG; Suman VJ; Fitch TR; Amatruda T; Morton RF; Jilani SZ; Constantinou CL; Egner JR; Kottschade LA; Markovic SN
    Cancer; 2009 Jan; 115(1):119-27. PubMed ID: 19090009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
    J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
    Flaherty KT; Lee SJ; Zhao F; Schuchter LM; Flaherty L; Kefford R; Atkins MB; Leming P; Kirkwood JM
    J Clin Oncol; 2013 Jan; 31(3):373-9. PubMed ID: 23248256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
    Jamal R; Lapointe R; Cocolakis E; Thébault P; Kazemi S; Friedmann JE; Dionne J; Cailhier JF; Bélanger K; Ayoub JP; Le H; Lambert C; El-Hajjar J; van Kempen LC; Spatz A; Miller WH
    J Immunother Cancer; 2017 Nov; 5(1):83. PubMed ID: 29157311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
    Di Pietro FR; Marinelli D; Verkhovskaia S; Poti G; Falcone R; Carbone ML; Morelli MF; Zappalà AR; Di Rocco ZC; Morese R; Piesco G; Chesi P; Marchetti P; Failla CM; De Galitiis F
    BMC Cancer; 2024 Oct; 24(1):1220. PubMed ID: 39354418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
    Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
    Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
    Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
    Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
    PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.
    Rao RD; Holtan SG; Ingle JN; Croghan GA; Kottschade LA; Creagan ET; Kaur JS; Pitot HC; Markovic SN
    Cancer; 2006 Jan; 106(2):375-82. PubMed ID: 16342250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
    Homsi J; Bedikian AY; Kim KB; Papadopoulos NE; Hwu WJ; Mahoney SL; Hwu P
    Melanoma Res; 2009 Aug; 19(4):238-42. PubMed ID: 19521262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.